Singular Genomics Systems announced the launch of its Max Read Kits for single cell applications on the company’s G4 Sequencing Platform at the Advances in Genome Biology and Technology, AGBT, 23rd General Meeting, taking place February 6-9, 2023, in Hollywood, Florida. The Max Read Kits boost the potential output of the G4 to a market-leading 3.2 billion reads per run on a benchtop system for single cell sequencing. The kits, specifically designed to match the format of popular 10x Genomics assays, enable users the flexibility to sequence 4, 8, 12, or 16 samples per run, each in its own lane. "We believe the combination of speed, flexibility, cost, and power that the Max Read Kits provide will firmly establish the G4 as the leading benchtop system for customers running single cell applications," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We look forward to sharing data at AGBT and to begin shipping to our customers in the second quarter of this year… We have seen consistent improvement on the throughput of our flow cells and, for certain applications, we are now achieving up to 1.8 billion reads per run on the F3 flow cells. We’ve been especially pleased with the quality of data coming from our F3 flow cells and are excited to start sending these to select customers later this month," added Spaventa.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMIC:
- Singular Genomics Launches Max Read™ Kits for Single Cell Sequencing on the G4 at AGBT
- Singular Genomics joins 10x Genomics Compatible Partner Program
- Singular Genomics Joins the 10x Genomics Compatible Partner Program
- Singular Genomics sees Q4 revenue about $700,000, consensus $650,000
- Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue